KR870005645A - New Cell Growth Regulator - Google Patents

New Cell Growth Regulator Download PDF

Info

Publication number
KR870005645A
KR870005645A KR860010968A KR860010968A KR870005645A KR 870005645 A KR870005645 A KR 870005645A KR 860010968 A KR860010968 A KR 860010968A KR 860010968 A KR860010968 A KR 860010968A KR 870005645 A KR870005645 A KR 870005645A
Authority
KR
South Korea
Prior art keywords
polypeptide
proliferation
inhibit
cells
acids
Prior art date
Application number
KR860010968A
Other languages
Korean (ko)
Other versions
KR920005920B1 (en
Inventor
엠. 자알링 조이스
쇼아브 모하메드
마르쿠아르트 한스
비. 한슨 마시아
엔. 리오우빈 마리오
요셉 브라운 토마스
Original Assignee
원본미기재
온코겐, 어 리미티드 파트너쉽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 온코겐, 어 리미티드 파트너쉽 filed Critical 원본미기재
Publication of KR870005645A publication Critical patent/KR870005645A/en
Application granted granted Critical
Publication of KR920005920B1 publication Critical patent/KR920005920B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

내용 없음No content

Description

신규세포 생장조절 인자New Cell Growth Regulator

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (18)

백혈구로 부터 얻을 수 있고, 종양세포의 증식을 억제할 수 있으며, 정상인의 섬유아세포의 증식을 촉진시키고, 인테증식 및 세포독소 T세포 응답을 억제시키지 않으며, 과립구/골수구의 골수군락세로의 형성을 억제시키지 않고, 겔추출 크로마토그래피법에 의해서 측정된 약 17-19KD 및 SDS-PAGE에 의해서 측정된 약 28KD 범위내의 분자량을 가지며, 보통의 산과 염기 및 적당히 상승된 온도에서 비교적 민감하지 않는 폴리펩티드인 화합물과 면역학적으로 교차반응성을 갖는 아미노산이 최소한 8개 이상인 신규의 폴리아미노산.Can be obtained from leukocytes, inhibit the proliferation of tumor cells, promote the proliferation of fibroblasts in normal humans, do not inhibit ingrowth and cytotoxin T cell responses, and form the myeloid colony of granulocytes / myelocytes Compounds having a molecular weight within the range of about 17-19 KD as determined by gel extraction chromatography and about 28 KD as determined by SDS-PAGE, without inhibition, which are relatively insensitive to normal acids and bases and moderately elevated temperatures Novel polyamino acids with at least eight amino acids that are immunologically cross reactive with one another. 제1항에 있어서, 첨부된 도면중에 제1도에 도시된 아미노산 배열에 해당하는 최소한 10개 이상의 연속적인 아미노산을 갖고 아미노산이 3개를 초과하지 아니하여 상기 배열과 다른 아미노산 배열을 포함하는 것이 특징인 폴리아미노산.The method of claim 1, wherein the accompanying drawings have at least 10 or more consecutive amino acids corresponding to the amino acid sequence shown in FIG. Phosphorus polyamino acid. 제1항에 있어서, 제1도에 도시된 아미노산 배열에 해당하고, 12개의 연속적인 아미노산을 포함하고 아미노산이 1개를 초과하지 아니하여 상기 배열과는 상이하고, 상기 상이한 점이 제거 또는 보호적인 치환에 있는 것이 특징인 폴리아미노산.The substitution according to claim 1, which corresponds to the amino acid sequence shown in FIG. 1 and comprises 12 contiguous amino acids and differs from the arrangement by not exceeding one amino acid, wherein the different points are removed or protected. Polyamino acids characterized by 종양세포의 증식을 억제할 수 있고, 정상인의 섬유아세포의 증식을 촉진시키며, 인체증식 및 세포독소 T세포 응답을 억제시키지 않고, 과립구/골수구의 골수군락세포의 형성을 억제하지 않으며, 겔 추출 크로마토그래피법에 의해서 측정된 약 17-19KD 및 SDS-PAGE에 의해서 측정된 약 28KD 범위내의 분자량을 갖고, 보통의 산과 염기 및 적당히 상승된 온도에서 비교적 민감하지 않고, 순수한 상태로 최소한 약 10GIA단위/ng 단백질 이상인 특수활성도를 제공하는 성분을 함유하는 백혈구에서 얻을 수 있는 신규의 폴리펩티드 조성물.It can inhibit the proliferation of tumor cells, promote the proliferation of fibroblasts in normal people, do not inhibit human proliferation and cytotoxin T cell response, do not inhibit the formation of granulocyte / myeloid myeloid colony cells, gel extraction chromatography It has a molecular weight within the range of about 17-19 KD as determined by the graphical method and about 28 KD as determined by SDS-PAGE, and is relatively insensitive to normal acids and bases and moderately elevated temperatures, at least about 10 GIA units / ng in a pure state. A novel polypeptide composition obtainable from leukocytes containing a component that provides a specific activity above protein. 제4항에 있어서, 상기 백혈구가 유사분열물질-활성화된 정상인의 주변혈액의 임파구인 것이 특징인 폴리펩티드 조성물.The polypeptide composition of claim 4, wherein said leukocytes are lymphocytes of peripheral blood of mitotic-activated normal persons. 제4항에 있어서, 상기 백혈구가 포르볼 디에스테르 유도 인체 조직구 임파종 세포인 것이 특징인 폴리펩티드 조성물.5. The polypeptide composition of claim 4, wherein said leukocytes are phorbol diester induced human histocytic lymphoma cells. 제4항에 있어서, 실질적으로 세포성분이 없는 것이 특징인 폴리펩티드 조성물.The polypeptide composition of claim 4, wherein the polypeptide composition is substantially free of cellular components. 상기 폴리펩티드의 특수활성도가 최소한 약 100GIA단위/ng단백질 이상인 것이 특징인 제4항의 조성물로 부터 얻은 폴리펩티드.A polypeptide obtained from the composition of claim 4, wherein the polypeptide has a specific activity of at least about 100 GIA units / ng protein or more. 종양세포의 증식을 억제할 수 있고, 정상인의 섬유아 세포의 증식을 촉진시키며, 인체증식 및 세포독소 T세포응답을 억제하지 않고, 과립구/골수구의 골수군락세포의 형성을 억제하지 않으며, 겔 추출 크로마토그래피법에 의해서 측정된 약17-19KD 및 SDS-PAGE에 의해서 측정된 약 28KD 범위내의 분자량을 갖고, 보통의 산과 염기 및 적당히 상승된 온도에서 비교적 민감하지 않으며, 제1도에 도시된 배열과는 차이점을 가진 아미노산을 3개 이상 초과하지 않는 것과 제1도에 도시된 배열에 해당하는 아미노산 배열을 포함하는 실질적으로 세포가 파괴된 흔적과 기타 임파구 단백질이 포함되지 않은 폴리펩티드.It can inhibit the proliferation of tumor cells, promote the proliferation of fibroblasts of normal people, do not inhibit human proliferation and cytotoxin T cell response, do not inhibit the formation of myeloid colony cells of granulocytes / myelocytes, gel extraction It has a molecular weight in the range of about 17-19 KD as determined by chromatography and about 28 KD as determined by SDS-PAGE, and is relatively insensitive at normal acids and bases and moderately elevated temperatures, and with the arrangement shown in FIG. Is a polypeptide that does not exceed three or more amino acids with differences and that contains substantially no cell traces and other lymphocyte proteins, including the amino acid sequence corresponding to that shown in FIG. 제9항에 있어서, 상기 해당하는 배열이 아미노산의 1개 이상을 초과하지 아니하며 상기 도시된 배열과 서로 다른 배열을 갖는 것이 특징인 폴리펩티드.The polypeptide of claim 9, wherein said corresponding arrangement does not exceed one or more of the amino acids and has a different arrangement from the depicted arrangement. 상기 세포를 제8항의 폴리펩티드 증식 억제량과 접촉시킴을 특징으로 하는 종양세포의 증식을 억제하는 방법.A method of inhibiting the proliferation of tumor cells, characterized in that the cell is contacted with the amount of the polypeptide growth inhibition of claim 8. 상처를 제8항의 폴리펩티드의 성유아세포 증식 촉진량과 접촉시킴을 특징으로 하는 상처의 치료를 향상시키는 방법.A method of improving the treatment of a wound, wherein the wound is contacted with an amount promoting sexual oocyte proliferation of the polypeptide of claim 8. 제1항 또는 제4항의 폴리펩티드 조성물에 특효인 항체.An antibody that is effective against the polypeptide composition of claim 1. 제13항에 따른 단일분지계 항체.Single branched antibody according to claim 13. 제4항의 조성물을 함유하는 것으로 생각되는 시료를 제13항의 항체와 결합시켜 상기 항체로써 복합체의 형성량을 측정하는 것이 특징인 제4항의 폴리펩티드 조성물의 존재를 검출하는 방법.A method for detecting the presence of the polypeptide composition of claim 4, wherein the amount of the complex formed with the antibody is measured by binding a sample believed to contain the composition of claim 4 with the antibody of claim 13. 제8항에 따른 폴리펩티드를 암호화한 DNA배열.DNA sequence encoding a polypeptide according to claim 8. 세포내에서 작용하는 전사 및 해독 조정신호의 표준조절하에 제4항의 폴리펩티즈를 암호화하여 폴리펩티드를 표현한 DNA배열로 구성되는 표현구성을 가진 세로를 함유하는 세포의 배양을 촉진시키고, 실질적으로 세포물질이 포함되지 않은 상기 폴리펩티드를 단리시킴을 특징으로 하는 제8항의 폴리펩티드를 제조하는 방법.Promotes the cultivation of cells containing serous cells having an expression structure consisting of DNA sequences expressing polypeptides by encoding the polypeptides of claim 4 under standard control of transcriptional and translational control signals acting within the cells, and substantially cellular material. The method of producing a polypeptide of claim 8, wherein said polypeptide is isolated. 제13항의 항체와 최소한 1개 이상의 제1항의 폴리아미노산 또는 제8항의 폴리펩티드로 구성된 진단용구.A diagnostic tool comprising the antibody of claim 13 and at least one polyamino acid of claim 1 or a polypeptide of claim 8. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019860010968A 1985-12-20 1986-12-19 Novel cell growth requlatory factor KR920005920B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81123585A 1985-12-20 1985-12-20
US811235 1985-12-20
US93528386A 1986-11-26 1986-11-26
US935283 1986-11-26
USP35283 1986-11-26

Publications (2)

Publication Number Publication Date
KR870005645A true KR870005645A (en) 1987-07-06
KR920005920B1 KR920005920B1 (en) 1992-07-24

Family

ID=27123452

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860010968A KR920005920B1 (en) 1985-12-20 1986-12-19 Novel cell growth requlatory factor

Country Status (29)

Country Link
JP (1) JP2559035B2 (en)
KR (1) KR920005920B1 (en)
CN (1) CN1017626B (en)
AT (1) AT400444B (en)
AU (2) AU601168B2 (en)
BE (1) BE905957A (en)
CA (1) CA1340296C (en)
CH (1) CH675727A5 (en)
CY (1) CY1608A (en)
DE (2) DE3645095C2 (en)
DK (1) DK174094B1 (en)
ES (1) ES2003180A6 (en)
FI (1) FI91484C (en)
FR (1) FR2597108B1 (en)
GB (1) GB2185485B (en)
GR (1) GR862936B (en)
HK (1) HK65691A (en)
HU (1) HU210694B (en)
IE (1) IE59415B1 (en)
IL (1) IL81017A (en)
IT (1) IT1213428B (en)
LU (1) LU86718A1 (en)
NL (1) NL8603209A (en)
NO (1) NO174556C (en)
NZ (1) NZ218634A (en)
OA (1) OA08494A (en)
PT (1) PT83986B (en)
SE (1) SE505059C2 (en)
SG (1) SG60891G (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US5681930A (en) * 1985-12-20 1997-10-28 Bristol-Myers Squibb Company Anti-oncostatin M monoclonal antibodies
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
ZA912137B (en) * 1990-03-29 1992-11-25 Oncogen Monocional antibodies that inhibit growth of kaposi's sarcoma
NO303226B1 (en) * 1990-03-29 1998-06-15 Bristol Myers Squibb Co Monoclonal antibody to Onkostatin M, as well as DNA molecule, cell line and hybridoma
WO1992002556A1 (en) * 1990-08-02 1992-02-20 Michael Valentine Agrez Human colon cancer cell-derived fibroblast elongation factor
IL107040A0 (en) * 1992-09-25 1993-12-28 Lilly Co Eli Modified platelet factor-4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132776A (en) * 1978-02-15 1979-01-02 University Patents, Inc. Delivery of immunologically active components of transfer factor
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits

Also Published As

Publication number Publication date
DK615386D0 (en) 1986-12-18
CA1340296C (en) 1998-12-29
FR2597108B1 (en) 1991-02-15
NZ218634A (en) 1991-06-25
DE3645095C2 (en) 1993-11-18
AU601168B2 (en) 1990-09-06
NO865178D0 (en) 1986-12-19
DK615386A (en) 1987-06-21
DE3643428C2 (en) 1990-08-23
IL81017A0 (en) 1987-03-31
NL8603209A (en) 1987-07-16
JPS62236498A (en) 1987-10-16
IT1213428B (en) 1989-12-20
AT400444B (en) 1995-12-27
SG60891G (en) 1991-08-23
LU86718A1 (en) 1988-07-14
CH675727A5 (en) 1990-10-31
ES2003180A6 (en) 1988-10-16
IT8622787A0 (en) 1986-12-19
CN86108955A (en) 1987-12-02
IE863345L (en) 1987-06-20
CY1608A (en) 1992-04-03
ATA340686A (en) 1995-05-15
NO865178L (en) 1987-06-22
FI865156A (en) 1987-06-21
FI865156A0 (en) 1986-12-17
HUT43103A (en) 1987-09-28
FR2597108A1 (en) 1987-10-16
GB8629997D0 (en) 1987-01-28
GB2185485B (en) 1990-07-04
IE59415B1 (en) 1994-02-23
DE3643428A1 (en) 1987-09-24
HK65691A (en) 1991-08-23
KR920005920B1 (en) 1992-07-24
NO174556C (en) 1994-05-25
OA08494A (en) 1988-07-29
AU6660886A (en) 1987-06-25
NO174556B (en) 1994-02-14
JP2559035B2 (en) 1996-11-27
SE505059C2 (en) 1997-06-16
HU210694B (en) 1995-06-28
GR862936B (en) 1987-10-28
BE905957A (en) 1987-06-17
DK174094B1 (en) 2002-06-10
SE8605459D0 (en) 1986-12-18
FI91484B (en) 1994-03-31
CN1017626B (en) 1992-07-29
SE8605459L (en) 1987-06-21
AU6776590A (en) 1991-03-14
PT83986A (en) 1987-01-01
AU639048B2 (en) 1993-07-15
IL81017A (en) 1993-01-14
GB2185485A (en) 1987-07-22
PT83986B (en) 1989-07-31
FI91484C (en) 1994-07-11

Similar Documents

Publication Publication Date Title
Schröder et al. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity.
Mizel et al. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1).
Kurlander et al. The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes
Lynch et al. Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells.
Postlethwaite et al. Generation of a fibroblast chemotactic factor in serum by activation of complement.
Domenicucci et al. Characterization of porcine osteonectin extracted from foetal calvariae
ATE78871T1 (en) PROTEIN COMPOSITION WITH COAGULATION EFFECT AND PROCESS FOR THEIR PRODUCTION.
DE19630557A1 (en) Tissue transglutaminase (EC 2.3.13, tTG), as an autoantigen of native sprue / celiac disease, which is specifically recognized by antibodies from sera from patients with native sprue; their use in diagnostics, therapy control and therapy of sprue, as well as other diseases / symptoms that are associated with an immune response against tTG
Baseler et al. Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responses
Hook et al. Histamine release by chemotactic, formyl methionine-containing peptides
KR870005645A (en) New Cell Growth Regulator
Villee et al. Effect of glucose and insulin on collagen secretion by human skin fibroblasts in vitro
Barrow et al. Kidney antihemophilic factor. Partial purification and some properties
Shiomi et al. Toxins in the skin secretion of the oriental catfish (Plotosus lineatus): immunological properties and immunocytochemical identification of producing cells
WO1987007146A1 (en) INHIBITOR OF C5a-MEDIATED CHEMOTAXIS
DE3667061D1 (en) New protein isolated from blood, process for preparing said protein, antibodies against said new protein, and pharmaceutical compositions containing said protein or said antibodies
Cicero et al. Turnover of the brain specific protein, S-100
KR890007751A (en) Cell growth inhibitory factor
Savage et al. Studies on IL-1 receptors on D10S T-helper cells: demonstration of two molecularly and antigenically distinct IL-1 binding proteins
Whiteside et al. Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture
Wyler et al. Direct and indirect effects of soluble extracts of Schistosoma mansoni eggs on fibroblast proliferation in vitro
Bloom et al. Toxinological and immunological studies of capillary electrophoresis fractionated Chrysaora quinquecirrha (Desor) fishing tentacle and Chironex fleckeri Southcott nematocyst venoms
Lester et al. Human alpha-fetoprotein: immunosuppressive activity and microheterogeneity
Fojo et al. The isolation and characterization of a colony stimulating factor from human lung
RosENoER et al. A transplantable plasma cell tumour in the study of carcinostatic agents

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060711

Year of fee payment: 15

EXPY Expiration of term